Core Insights - NVE Corporation reported a 23% increase in quarterly revenue and an 11% rise in net income, driven by strong product sales and a significant increase in contract R&D revenue [3][6][7] Financial Performance - Operating expenses decreased by 12% year over year, with R&D expenses down by 9% and SG&A expenses down by 19% [1] - Gross margin fell to 79% from 84% due to a less profitable product mix and a higher proportion of distributor sales [2][6] - Net income for the quarter was $3.38 million, or $0.70 per diluted share, compared to $3.05 million, or $0.63 per share, in the prior-year quarter [7] Revenue Breakdown - Revenue growth was attributed to a 16% increase in product sales and a remarkable 335% increase in contract R&D revenue [3][6] - For the first nine months of fiscal 2026, total revenue increased by 0.4% to $18.7 million, driven by a 0.8% rise in product sales, despite an 8% decline in contract R&D [12] Operational Developments - The company has nearly completed a multi-year expansion, with new equipment expected to be operational by March 31, enabling the production of smaller and more precise wafer-level chip scale sensors [5][15][17] - NVE extended its supplier agreement with Abbott through December 31, 2027, which includes price increases [4][19] Market and Product Strategy - The company is focusing on high-value MRAM opportunities through licensing rather than building large fabs [4][26] - NVE is targeting high-value markets with new wafer-level chip scale sensors measuring 0.65 millimeters square, enhancing miniaturization and spatial sensitivity [18][26] Customer and Distributor Insights - Distributor sales have been increasing, indicating that inventories built during the semiconductor slowdown have been depleted, leading to rising end-user demand [21][22] - The company participated in the Medical Design and Manufacturing Trade Show, generating positive leads for its products [20]

As filed with the Securities and Exchange Commission on November 17, 2025 Registration No. 333- UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM S-1 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 NAVITAS SEMICONDUCTOR CORPORATION (Exact name of registrant as specified in its charter) (State or other jurisdiction of incorporation or organization) If this Form is filed to register additional securities for an offering pursuant to Rule 462(b) under the Securities Act, pleas ...